Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Immunovant, Inc.NASDAQ: IMVT
Operating Income · Q2 FY2027 · quarter ended Sep 2026
Operating income remains negative
Q2 FY2027 operating income was -$104.16M, compared with -$131.76M a year earlier. Trailing-twelve-month operating income was -$531.3M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Mar 2027, a step up from the -21.6% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$104.16M+32.0% QoQ
- Last fiscal yearMar 2026
- -$532.9M-21.6% YoY
- LTMSep 2026
- -$531.3M-9.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.0% | +100.0% | +79.0 pp |
| 1 year | -21.6% | +100.0% | +121.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2026
- (532.9M) USD
- Year-over-year change
- -21.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (532.9M) | -21.6% |
| FY2025 | 2025-03-31 | (438.15M) | -62.2% |
| FY2024 | 2024-03-31 | (270.21M) | -29.7% |
| FY2023 | 2023-03-31 | (208.28M) | -33.5% |
| FY2022 | 2022-03-31 | (156.03M) | — |
Operating Income vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 operating income of -$531.3M is the lowest of the 11 companies compared; the peer median is -$144.32M.
- Its year-over-year change of -9.1% is the 7th highest of 11, against a peer median of -3.7%.
- Operating income amounts to 7488.4% of revenue for IMVT, versus a peer median of 30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $192.86M | +87.6% | — | 21.5% | |
| LTM Mar 2026 | $40.8M | +140.7% | — | 17.6% | |
| LTM Mar 2026 | $21.41M | +133.7% | — | 39.8% | |
| LTM Mar 2026 | -$80.48M | +43.0% | — | 961.9% | |
| LTM Mar 2026 | -$109.64M | -8.6% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | -$179.01M | +1.2% | — | — |
| LTM Mar 2026 | -$179.4M | -33.6% | — | — | |
| LTM Mar 2026 | -$205.06M | -12.1% | — | — | |
| LTM Mar 2026 | -$240.35M | -15.0% | — | — | |
| LTM Mar 2026 | -$423.08M | -143.7% | — | — | |
| LTM Sep 2026 | -$531.3M | -9.1% | — | 7488.4% | |
| Peer median (excluding IMVT) | -$144.32M | -3.7% | — | 30.7% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.